医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promega PowerQuant™ System Enables More Informed Casework Decisions

2015年03月19日 PM10:00
このエントリーをはてなブックマークに追加


 

MADISON, Wis.

Promega Corporation announces the release of the PowerQuant™ System, a probe-based 4-target, 5-dye real-time PCR method. The system allows laboratories to determine human and male DNA concentrations in a sample, assess the integrity of the DNA sample and detect possible PCR inhibitors in approximately one hour.

Promega PowerQuant(TM) System allows laboratories to determine human and male DNA concentrations in  ...

Promega PowerQuant(TM) System allows laboratories to determine human and male DNA concentrations in a sample, assess the integrity of the DNA sample and detect possible PCR inhibitors. (Photo: Business Wire)

The PowerQuant System ensures that DNA detected in the quantification step of the workflow equates to a usable STR profile. Accurate and sensitive DNA quantification plays a key role in ensuring successful STR results, and because many samples are precious, getting it right the first time is critical. Inaccurate determination of the amount of DNA present in the sample can lead to unusable STR profiles, and repeating the STR assay with corrected DNA template amounts can waste both reagents and a user’s time.

PowerQuant also allows laboratories to assess the quality of the DNA sample, whether it is the integrity of the DNA or the presence of possible PCR inhibitors. By correctly doing so, laboratories can make informed decisions about processing difficult casework samples.

Using the PowerQuant System, along with the PowerQuant™ Analysis Tool program, for quality assessment and STR normalization values, laboratories are able to make the best decision about what steps to take next in their workflow and eliminate guesswork about DNA samples.

Developmental validation efforts are under way. To learn more, please visit: www.promega.com/powerquant.

About Promega

Promega Corporation has provided products for DNA-based human identification for over 20 years. Promega is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 3,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150319005043/en/

CONTACT

Promega Corporation
Penny Patterson
Sr. Director,
Communications
(608) 274-4330
penny.patterson@promega.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続